Alignment Healthcare (NASDAQ:ALHC) Shares Gap Down – What’s Next?

Alignment Healthcare, Inc. (NASDAQ:ALHC)’s share price gapped down before the market opened on Friday . The stock had previously closed at $20.42, but opened at $18.84. Alignment Healthcare shares last traded at $20.0470, with a volume of 950,841 shares traded.

Trending Headlines about Alignment Healthcare

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Q4 results beat near‑term expectations — Alignment reported ($0.05) EPS vs. consensus (~$0.15 loss) and revenue of ~$1.01B, up ~44% year‑over‑year, showing strong top‑line growth. Alignment Healthcare Reports Fourth Quarter and Full‑Year 2025 Results
• Positive Sentiment: Company highlighted record revenue and membership gains, supporting continued Medicare Advantage enrollment momentum that underpins revenue visibility. Alignment Healthcare Inc (ALHC) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Analyst writeups and metric comparisons confirmed the beat but note persistent negative margins and ROE; these pieces provide context on profitability trends and model updates. Zacks — Key Metrics Versus Estimates
• Neutral Sentiment: Conference call / press release and filings are available for details on membership trends, medical cost assumptions and guidance drivers for 2026. Quarterly Report / Press Release PDF
• Neutral Sentiment: Reported short‑interest data in public feeds appears erroneous (zeros/NaN); no reliable short‑interest signal from those entries. Market data / profile
• Negative Sentiment: Forward guidance disappointed: Q1 revenue guidance (~$1.2B) below the ~ $1.3B street estimate and FY 2026 revenue guidance of $5.1B–$5.2B sits at or slightly under consensus — investors reacted to the softer top‑line outlook. Guidance details in Earnings Release
• Negative Sentiment: Profitability remains a concern — the company still shows a small negative net margin and negative return on equity, and management did not provide explicit EPS guidance for 2026, leaving investors uncertain on near‑term earnings conversion. Zacks — Q4 Loss, Beats Revenue Estimates

Wall Street Analysts Forecast Growth

Several analysts have weighed in on ALHC shares. Piper Sandler upped their price objective on shares of Alignment Healthcare from $20.00 to $30.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 6th. Wall Street Zen upgraded Alignment Healthcare from a “hold” rating to a “buy” rating in a research report on Saturday, February 7th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $22.00 price target on shares of Alignment Healthcare in a report on Monday, November 3rd. JPMorgan Chase & Co. boosted their price objective on Alignment Healthcare from $23.00 to $26.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Alignment Healthcare in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Alignment Healthcare presently has an average rating of “Moderate Buy” and a consensus target price of $23.95.

Alignment Healthcare Trading Down 5.9%

The company has a market capitalization of $3.85 billion, a price-to-earnings ratio of -1,920.08, a P/E/G ratio of 4.90 and a beta of 1.16. The company has a debt-to-equity ratio of 1.99, a quick ratio of 1.61 and a current ratio of 1.61. The business’s 50-day simple moving average is $20.99 and its 200-day simple moving average is $18.54.

Alignment Healthcare (NASDAQ:ALHC) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.10. Alignment Healthcare had a negative net margin of 0.02% and a negative return on equity of 0.53%. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period in the previous year, the firm posted ($0.16) earnings per share. Alignment Healthcare’s revenue for the quarter was up 44.4% compared to the same quarter last year. On average, research analysts expect that Alignment Healthcare, Inc. will post -0.69 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Robert L. Scavo sold 69,541 shares of the firm’s stock in a transaction on Monday, December 29th. The stock was sold at an average price of $18.74, for a total value of $1,303,198.34. Following the transaction, the insider directly owned 503,014 shares in the company, valued at $9,426,482.36. This trade represents a 12.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, President Dawn Christine Maroney sold 282,070 shares of the company’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $18.74, for a total value of $5,285,991.80. Following the completion of the sale, the president owned 1,385,167 shares of the company’s stock, valued at $25,958,029.58. This represents a 16.92% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 2,125,938 shares of company stock valued at $41,799,570 in the last 90 days. 7.00% of the stock is owned by company insiders.

Institutional Trading of Alignment Healthcare

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Royal Bank of Canada boosted its stake in Alignment Healthcare by 92.6% during the 1st quarter. Royal Bank of Canada now owns 92,379 shares of the company’s stock worth $1,720,000 after acquiring an additional 44,413 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Alignment Healthcare by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,557 shares of the company’s stock valued at $1,109,000 after purchasing an additional 2,594 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in Alignment Healthcare by 79.1% in the first quarter. Goldman Sachs Group Inc. now owns 972,715 shares of the company’s stock worth $18,112,000 after purchasing an additional 429,703 shares during the period. Woodline Partners LP bought a new position in shares of Alignment Healthcare during the first quarter worth $2,142,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Alignment Healthcare by 16.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 307,655 shares of the company’s stock valued at $5,729,000 after buying an additional 44,452 shares during the period. 86.19% of the stock is owned by institutional investors.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.